MetaCap

Alnylam Pharmaceuticals (ALNY) vs Ascendis Pharma A/S (ASND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ascendis Pharma A/S (ASND) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 20.1% versus a loss of 67.0%. Over five years, ASND leads with a +75.7% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $16.58 billion), about 1.2 times the size.

On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (14.5x vs 20.5x for Ascendis Pharma A/S).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALNY-67.04%ASND+20.07%
+37%-18%-72%
Nov 21, 20251 yearNov 20, 2026
ALNY-20.54%ASND+69.83%
+177%+57%-64%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALNY versus ASND key metrics
MetricALNYASND
Share price$143.82$252.73
Market cap$19.26B$16.58B
1-day change-2.71%-1.26%
YTD return-63.83%+18.52%
1-year return-67.04%+20.07%
5-year return-23.72%+75.73%
P/E ratio (TTM)7.2616.62
Forward P/E14.5120.47
EPS (TTM)$19.80$15.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.71B—
Revenue growth (YoY)+65.19%—
Net income (latest FY)$313.75M—
Gross margin81.77%—
Operating margin13.51%—
Net margin8.45%—
52-week high$479.79$282.15
52-week low$143.40$188.08
Distance from 52-week high-70.02%-10.43%
Analyst consensusbuystrong_buy
Avg. price target upside+101.10%+24.95%
Average volume2.09M750.65K
Shares outstanding133.94M65.60M
Employees2,5001,189
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ASND has outperformed ALNY by 87.1 percentage points over the past year.
  • Ascendis Pharma A/S trades at a higher earnings multiple (16.6x vs 7.3x trailing P/E).

About Alnylam Pharmaceuticals

ALNY stock →

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees

About Ascendis Pharma A/S

ASND stock →

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees

ALNY vs ASND FAQ

Which is bigger, Alnylam Pharmaceuticals or Ascendis Pharma A/S?

Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $16.58B for Ascendis Pharma A/S (ASND).

Which stock has performed better over the past year, ALNY or ASND?

ASND returned +20.07% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ALNY or ASND?

ALNY has the lower trailing P/E at 7.3, versus 16.6 for ASND. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Alnylam Pharmaceuticals and Ascendis Pharma A/S in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons